Crest View International financial executives have commented on Takeda as they sell Japanese Consumer Health Unit to Blackstone for $2.3 billion. Contacts Mr. Nathan Hu, Head of Research.

D octors and investors are getting their first glimpse of the data that compelled Takeda Pharmaceutical to make a $6 billion bet on an experimental pill. The drug, which it acquired from Boston ...

With Takeda slated to unveil its first-quarter earnings later this week, analysts will be keen to see whether the Tokyo-based pharma will use the opportunity to flesh out its refocused R&D strategy.

W ASHINGTON — Takeda Pharmaceuticals has left the biotechnology industry’s main lobbying group, the fourth departure of a major member since December, the company confirmed. “Takeda decided ...

Takeda Pharmaceutical will buy U.S.-based Nimbus Therapeutics' experimental psoriasis drug for up to $6 billion, the Japanese drugmaker said on Tuesday, as it looks to cut reliance on treatments ...

Takeda isn’t saying which dose of TAK-279 it plans to advance to Phase 3, but Plump noted that the clear separation on the 100% clearance measure at 30 mg has the company looking closely at ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches. Skip to content. Home page Seeking Alpha - Power to Investors.

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.

One of the European Commission’s stipulations for Takeda’s purchase of Shire was that it divest the biopharma’s inflammatory bowel disease candidate SHP647.

More job cuts are coming at Takeda Pharmaceuticals Inc. just a few weeks after the pharmaceutical giant announced it planned to lay off 641 Massachusetts employees.

On Friday, Takeda notified the state Executive Office of Labor and Workforce that it is laying off 79 employees in September. The layoffs include 45 at Takeda’s Cambridge site and 34 at its ...

Takeda has also lost patent protection on its blood pressure medicine Azilva in Japan. Takeda has said it won’t face competition from generic versions of its other drugs until the early 2030s.